Open AccessParkinson's disease (PD) is the most common neurodegenerative disease
Author(s) -
Pavel A. Andoskin,
А. К. Емельянов,
Михаил Николаев,
Konstantin Senkevich,
В. П. Шилин,
А. А. Тимофеева,
А Ф Якимовский,
С. Н. Пчелина
Publication year - 2015
Publication title -
učënye zapiski sankt-peterburgskogo gosudarstvennogo medicinskogo universiteta im. akad. i.p. pavlova/učënye zapiski sankt-peterburgskogo gosudarstvennogo medicinskogo universiteta imeni akademika i. p. pavlova
Language(s) - English
Resource type - Journals
eISSN - 2541-8807
pISSN - 1607-4181
DOI - 10.24884/1607-4181-2015-22-2-14-17
Subject(s) - alpha synuclein , biomarker , parkinson's disease , dopamine , alpha (finance) , medicine , hemolysis , disease , chemistry , biochemistry , surgery , construct validity , patient satisfaction
Metabolic impairment of alpha-synuclein protein is considered to be the central event in PDpathogenesis. Recent studies explored usage of alpha-synuclein in peripheral fluids as a biomarker of PD, however alpha-synuclein level in the CSF and plasma is considered to be affected by hemolysis. In order to avoid contamination of a lymphocyte fraction by erythrocytes, we have proposed an algorithm based on measurements of alpha-synuclein levels in the homogeneous CD45+ cell blood fraction. For this study we formed a group of PD patients (N=14) and a control group without the neurological disorders (N=17). We found an increase in the level of the total alpha-synuclein in CD45+ cells of PD patients compared to controls (p = 0,04), and revealed a direct correlation between the level of dopamine in plasma and level of total alpha-synuclein in CD45+ cells in the control group (r=0,71, p = 0,007).The level of alpha-synuclein in CD45+ cells could be suggested as possible PD biomarker.